CLOUDR (09955) released its interim results, with revenue of 629 million yuan. The operational situation remains stable and solid after the strategic transformation.

CLOUDR (09955) announced its interim results for the six months ending June 30, 2026, reporting revenue of 629 million yuan, a decrease of 29.5% year-on-year; adjusted net loss of 8.86 million yuan, a decrease of 86% year-on-year; and a loss per share of 0.05 yuan. During the period, the decline in revenue was primarily due to the adverse impact of the centralized procurement policy on both inpatient and outpatient solutions, as well as a strategic exit from low-profit and cash-consuming value-added services. However, by focusing on high-quality and cash-generating growth rather than quantity growth, our gross margin increased from 37.1% for the six months ending June 30, 2025, to 46.7% for the six months ending June 30, 2026. For the six months ending June 30, 2026, our adjusted net loss under non-IFRS standards was 8.9 million yuan, a significant improvement of 86.0% year-on-year, indicating solid operational conditions following the strategic transformation. The AI-driven hospital platform has significantly enhanced customer stickiness, thereby increasing our commercialization opportunities. Our inpatient solutions have successfully established deep connections with hospitals and pharmaceutical companies, laying a solid foundation for expanding our business into outpatient scenarios. As of the six months ending June 30, 2026, the number of hospitals connected to our hospital platform reached 15,266, a decrease of 571 hospitals or 3.6% compared to the six months ending June 30, 2025. This reduction is mainly attributed to the strategic exit from certain low-tier hospitals with poor performance. However, the number of tertiary hospitals increased by 482 or 49.8% compared to the six months ending June 30, 2025.